Datapoint: FDA Approves Zynlonta for DLBCL

The FDA on April 23 approved ADC Therapeutics’ Zynlonta for the treatment of diffuse large B-cell lymphoma (DLBCL) in adult patients who have received two previous therapies. Zynlonta is the first single-agent CD19-targeted antibody drug conjugate approved to treat the disease. Other novel therapies approved to treat DLBCL in recent years include Novartis’ Kymriah, which holds covered or better status for 29% of all insured lives under the pharmacy benefit, and Gilead Sciences’ Yescarta, which is covered or better for 30% of all lives.

SOURCE: MMIT Analytics, as of 4/26/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 24

Datapoint: Keytruda Scores Major Kidney Cancer Nod

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 23

Datapoint: Zing Health Acquires Lasso Healthcare

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 22

Datapoint: Paramount Loses Ohio Medicaid Battle

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today